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vs MM (41%), HL (40%) and AL/LCD (23%); p ¼ 0.004. The
median number of CD34 cells collected was 7.4 million/kg
(IQR 5.2- 9.9). Median CD34 collection was highest for MM
and AL/LCD, reﬂecting the practice to collect for more than
one transplant. Overall 9 (<1%) and 22 (2%) patients collected
< 2 million and < 2.5 million CD34 cells/kg, respectively.
More patients with NHL (4%) collected < 2.5 million/kg
compared with MM (1%), AL/LCD (2%) and HL (0%), p¼0.02.
The median number of days of apheresis was 2 (IQR 1-3) and
was higher in the NHL group (p¼0.002). The median CD34
collected per day was 3.6 million/ kg (IQR 2-5.8); higher in
MM and AL/LCD vs NHL and HL (p < 0.001). The median
CD34 collection was very similar for those patients getting
plerixafor versus those not requiring plerixafor (p¼0.26). The
median time to ANC and platelet engraftment were 14 days
(IQR 13-16) and 13 days (IQR 12-15), respectively. While
there was no difference in ANC engraftment, platelet
engraftment was longer among patients requiring plerixafor.
Conclusion: This data conﬁrms the effectiveness of this risk
adapted algorithm in over 1000 patients over 4 years. The
mobilization failure rate remains low. Approximately 45% of
patients did not require plerixafor, supporting the use of this
risk adapted algorithm to select appropriate patients who
require plerixafor.CLINICAL CELLULAR THERAPY32
In Vivo Expansion of NK Cells Stimulated with PM21
Particles Under Ultralow IL-2
Jeremiah L. Oyer 1, Veethika Pandey 1, Dominic A. Colosimo 1,
Robert Y. Igarashi 1, Ahmed Zakari 2, Melhem Solh 3,
Deborah A. Altomare 1, Alicja J. Copik 1. 1 Burnett School of
Biomedical Sciences, University of Central Florida, Orlando, FL;
2 Cancer Institute of Florida, Florida Hospital, Orlando, FL;
3 Florida Hospital Cancer Institute, Orlando, FL
Cancer immunotherapy with NK cells is promising, but a
key challenge is the development of a method that can
consistently expand NK cells from a small fraction (w5%)
of unselected PBMCs to a therapeutically effective dose
while using “off the shelf” reagents, not requiring long-
term complex co-cultures, and with low doses of IL-2.
Methods that use feeder cells do expand NK cells, but
require complex procedures with prolonged ex vivo co-
culture with the feeder cells, are costly, are logistically
difﬁcult, and require subsequent administration of high
dose IL-2 for persistence after injection. We developed a
particle-based method to speciﬁcally expand cytotoxic NK
cells from unselected PBMCs. These particles, prepared
from plasma membrane (PM) of engineered K562 cells
that express cytokines such as IL-21 or IL-15 and 41BBL,
stimulate in vitro and in vivo expansion of NK cells. In vitro,
these PM-particles containing membrane bound IL-21
(PM21-particles) cause highly speciﬁc expansion of cyto-
toxic NK cells from unselected PBMCs by achieving >90%
NK cells in 14 days and 104 fold expansion of NK in 21
days. NK cell expansion is consistent with different prep-
arations of PM-particles or leukocyte sources, and the PM-
particles retain expansion efﬁcacy with -80C storage.
The PM21-particles also stimulate in vivo NK cell expan-
sion in NSG mice under ultralow IL-2 (1,000 U per injec-
tion, 3 x weekly). The efﬁcacy of ex vivo pre-activation
with PM21, prior to injection, was tested by injecting
PBMCs (2 x 106 PBMCs per mice, i.p., 6 mice per group),which were either activated in culture for two days with
200 mg/mL PM21 (PM21-PBMCs) or not pre-activated
(PBMCs), and then the abundance of hCD56+CD3- NK cells
and other hCD45+ lymphocytes were monitored in pe-
ripheral blood of mice. Clear efﬁcacy for pre-activation
was observed where the mice in the group given PM21-
PBMCs had 66 fold higher human NK (hNK) cells as
compared to the group injected with PBMCs. The efﬁcacy
of administering PM21-particles in vivo was examined also
where 2 x 106 PM21-PBMCs, were injected i.p. into mice (4
mice per group) that then received 0, 400, 800 or 1600 mg
of PM21 (i.p., 2 x weekly). The mice injected with 800 mg of
PM21 had the highest amount of hNK cells averaging
890,000 hNK/mL of mouse blood on day 16 and reaching
95  2% of total hCD45+ cells by day 12. By comparing the
averages between day 5 and 16 in this experimental group,
hNK cell increased a minimum of 390 fold in the mouse
blood. Furthermore, examination of organs from mice
sacriﬁced on day 16 after PM21-PBMC injection shows
signiﬁcant numbers of hNK cells in bone marrow, spleen,
lung, liver and brain. The extent of NK cells observed in
the peripheral blood (>50,000 NK cells/mL blood, 14 days
post injection) and biodistribution to sites of disease
would be relevant for clinical cancer treatment, and thus
shows that PM-particle technology could be suitable for
NK cell immunotherapy.33
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Adoptive transfer of CMVpp65-speciﬁc T-cells (cCTL) from
CMV-seropositive (CMVpos) donors effectively restores
antiviral-immunity after stem cell transplantation. However,
the naïve T-cells in cord blood(CB) and adult CMV-serone-
gative(CMVneg) donors require different culture systems to
generate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and CMVnegs and
found that of >20 T-cell lines, all recognized atypical epi-
topes of pp65. HLA-A2+ cCTL derived from naive T-cells
recognized novel pp65 epitopes (e.g. LQT) but not the
typical epitope NLV. Analysis of the avidity of naïve donor
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avidity was similar to that of CMVpos CTL recognizing
typical epitopes (mean: 300pM), but 30x more avid than
paired CMVpos CTL recognizing atypical epitopes (P<0.05).
TCR sequencing performed on T-cells speciﬁc for typical
(CMVpos) and atypical (CMVpos,CMVneg, and CB) epitopes
revealed that CMVpos donor cCTL recognizing typical epi-
topes were less polyclonal (P¼0.02). To address the concern
that atypical epitopes might not be naturally presented by
CMV-infected cells and therefore not expanded in CMVpos
donors in response to virus infection, we tested whether
cCTL generated using CMV-infected ﬁbroblasts would
recognize the same epitopes. CMVpos cCTL recognized
typical epitopes while CB/CMVneg cCTL recognized only
atypical epitopes, suggesting that the epitopes are naturally
processed/presented by APCs. Using deep T-Cell receptor
(TCR) sequencing we identiﬁed TCRs recognizing typical and
atypical epitopes. When we searched for these sequences in
unmanipulated cord blood units, ﬁve different TCRs recog-
nizing atypical epitopes were found in 5/5 CB units whereas
of 22 NLV sequences, only 1 sequence was found in 1/5 cord
blood units suggesting that T-Cells recognizing atypical
epitopes are more prevalent during the primary infection
and are later replaced by T-Cells recognizing typical epi-
topes. These results reveal major, previously unreported
differences in the naïve and memory CMV speciﬁc T-cell
repertoire but suggest that atypical epitopes may indeed be
important. Indeed, in a clinical trial of CB-derived virus-
speciﬁc T-Cells, one patient with active CMV viremia
received three doses of virus-speciﬁc T-Cells and was ulti-
mately able to clear the virus with detectable CMV-speciﬁc
T-Cells in the peripheral blood of the patient post-ﬁrst T-Cell
infusion.
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Background: Patients (pts) with acute leukemia are
increasingly receiving RIC allo-SCT. Previously we have
shown that peripheral blood (PB) or bone marrow (BM)
grafts are associated with similar outcome after RIC MRD or
MUD allo-SCT for AML in remission. In current analysis we
have expanded study populations to include transplants
until 2012 from matched and mismatched (MM) donor in
both AML and ALL at any disease stage at transplant.
Methods: Pts who underwent related or unrelated donor RIC
PB or BM transplant from Jan 2000 to Dec 2012 were
included in the study. All unrelated donors were HLA-allele
matched (10/10) or 1 allele MM (9/10) (-A, -B, -C, DRB1,
-DQB1). Survival (OS) and DFS were estimated by Kaplan-
Meier. Relapse incidence (RI), NRM, engraftment, acute and
chronic GVHD were calculated using cumulative incidence
(CInc) methods. Risk factors for outcomes were analyzed by
Cox and Fine models.
Results: 837 pts transplanted with BM and 9011 with PB
after RIC regimens were compared. Among related donor,
5139 (52.6%) were geno-identical (BM¼388, PB¼4751) and
538 (5.5%) were MM (BM¼122, PB¼416). Of unrelated
donor, 3114 (31.6%) were 10/10 matched (BM¼220,
PB¼2894) and 1057 (10.7%) were 9/10 MM (BM¼107,
PB¼950). Median follow-up was 27 months for entire
cohort (BM 29, PB 27; p¼0.27). 8777 (89.1%) pts had AML
(BM¼702, PB¼8075) and ALL 1071 (10.9%) (BM¼135,
PB¼936). 5668 pts were in CR1 (BM¼475, PB¼5193), CR2+
1690 (BM¼177, PB¼1513) and 2490 had advanced disease
(BM¼185, PB¼2490). There were no statistically signiﬁcant
differences in cytogenetic risk categories among AML or ALL
for pts receiving BM or PB allo-SCT. CInc of engraftment was
lower in BM pts, 88 vs. 95.4% (p<0.0001). Grade II-IV
aGVHD was lower in BM (19.4%) vs. 23.8% in PB (p¼0.005).
cGVHD was more frequent after PB (36.2 vs. 28.9%,
p¼0.0003). RI was signiﬁcantly higher among BM recipients
(43 vs. 35.4%, p¼0.0004) whereas NRMwas not signiﬁcantly
different with the either stem cell source (p¼0.19). In
multivariate analysis, OS (HR 0.90, 95% CI 0.81-1.0; p¼0.05)
and DFS (HR 0.88, 0.79-0.97; p¼0.01) were higher in pts
transplanted with PB compared to BM. Furthermore, PB was
also associated with decreased risk of relapse (HR 0.78, 95%
CI 0.69-0.88; p¼0.00006).NRM was not signiﬁcantly
different between BM and PB and cGVHD was signiﬁcantly
lower after BM grafts (HR 1.38, 95%CI 1.18-1.61; p¼0.00008).
When analyzing separately ALL and AML pts, multivariate
analysis showed PB grafts was signiﬁcantly associated
higher LFS for AML, but not for ALL and no signiﬁcant dif-
ference OS between PB and BM groups.
Conclusion: Despite the limitation of a retrospective reg-
istry based study, our study shows that transplants with PB
from matched or MM related or unrelated donor after RIC
give the best outcomes. However, increased risk of cGVHD
after PB grafts is alarming and long-term follow-up is
needed to see if cGVHD related deaths might increase risk of
late NRM.35
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